Friday-Sunday, February 21-23, 2020, Miami, Florida

The Second Annual Miami General Medical Oncology Symposium

Dates
February 21-23, 2020

Location
JW Marriott Miami Turnberry
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: 305-932-6200

Meeting Room
King Ballroom (Conference Level)

Hotel Accommodations
A special discounted room rate of $339 (plus applicable tax and facilities fee) is available to conference attendees at the JW Marriott Miami Turnberry. Please see the Location tab for additional details.

 

Note from the Moderator

This coming February will mark the Second Annual General Medical Oncology Conference. This one-of-a-kind offering will span parts of 3 days and feature a stellar multidisciplinary faculty panel and a unique blend of short didactic presentations, lively moderated panel discussions and dedicated Q&A sessions. To augment the conference’s interactivity, each clinician will be provided with a specially configured iPad® to use throughout the program to participate in audience polling, view all the presentation slides and anonymously submit questions to the panelists for the Q&A. The conference’s educational design and the topics that will be discussed offer interested clinicians the opportunity to access the in-depth perspectives of some of the top minds in the field regarding significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with cancer.

So as you begin to make your plans for 2020, we hope you will join us in sunny South Florida for a learning experience unlike any other out there.

Moderator
Neil Love, MD
Research To Practice
Miami, Florida

Faculty:

Friday

Keynote Session: Chronic Lymphocytic Leukemia

Anthony R Mato, MD, MSCE
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Additional faculty to be announced

Saturday

Colorectal and Gastric Cancer

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

John L Marshall, MD
Chief, Hematology and Oncology
Director, Ruesch Center for the Cure
of GI Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Hepatocellular Carcinoma and Pancreatic Cancer

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine
and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead
Division of Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona

Wells A Messersmith, MD
Professor and Head, Division of Medical Oncology
Associate Director for Translational Research
University of Colorado Cancer Center
Aurora, Colorado

Dermatologic Cancers

Jason J Luke, MD
Associate Professor and Director of the Cancer
Immunotherapeutics Center
University of Pittsburgh Medical Center and
Hillman Cancer Center
Pittsburgh, Pennsylvania

Jeffrey S Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York

Hodgkin and Non-Hodgkin Lymphomas

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Mitchell R Smith, MD, PhD
Professor of Medicine
Associate Center Director for Clinical Investigations
Director, Division of Hematology and Oncology
GW Cancer Center
Washington, DC

Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy

Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Acute Leukemias

Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine at the
University of Pennsylvania
Member, Leukemia Program
Abramson Cancer Center of the
University of Pennsylvania
Philadelphia, Pennsylvania

Eytan M Stein, MD
Assistant Attending Physician
Director, Center for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Gynecologic Cancers

Michael J Birrer, MD, PhD
Director, O’Neal Comprehensive Cancer Center

Professor of Medicine/Hematology and Oncology
Evalina B Spencer Chair in Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in
Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

ER-Positive, HER2-Negative Breast Cancer

Erika Hamilton, MD
Director, Breast and Gynecologic
Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in
Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

HER2-Positive and Triple-Negative Breast Cancer

Charles E Geyer Jr, MD
Deputy Director
Houston Methodist Cancer Center
Houston, Texas

Rita Nanda, MD
Director, Breast Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois

Sunday

Prostate Cancer

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director
University of Virginia Cancer Center
Associate Director for Clinical Research
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in
Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Renal Cell Carcinoma and Bladder Cancer

William K Oh, MD
Chief, Division of Hematology and
Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical
Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Daniel P Petrylak, MD
Professor of Internal Medicine (Medical
Oncology) and Urology
Yale University
New Haven, Connecticut

Head and Neck Cancer

Faculty to be announced

Immune Checkpoint Inhibitors in Lung Cancer; Management of Wild-Type Disease

Hossein Borghaei, DO, MS
Associate Professor
Chief, Thoracic Medical Oncology
Co-Leader, Thoracic Cancer Service Line
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Stephen V Liu, MD, PhD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Targeted Treatment of Lung Cancer

Leora Horn, MD, MSc
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Additional faculty to be announced


 
Full agenda and speaker information will be made available later this year. Times and schedule are subject to change.

Preliminary Agenda

Friday, February 21st
  • 6:30 PM – 7:00 PM
  • 7:00 PM – 7:30 PM
  • 7:30 PM – 8:30 PM
  • Welcome Reception
  • Keynote Presentation
  • Panel Discussion and Moderated Q&A Session
Saturday, February 22nd
  • 7:00 AM – 8:00 AM
  • 8:00 AM – 12:25 PM
  • 12:25 PM – 1:10 PM
  • 1:10 PM – 4:45 PM
  • Breakfast
  • Morning General Session
  • Lunch
  • Afternoon General Session
Sunday, February 23rd
  • 7:00 AM – 8:00 AM
  • 8:00 AM – 12:30 PM
  • 12:30 PM
  • Breakfast
  • General Session
  • Meeting adjourns
 

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Accreditation Statements
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements
This educational activity for 12.75 contact hours is provided by Research To Practice.

This activity is awarded 12.75 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

CME Credit Form
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP, ACCME or the ANCC. Any off-label use as declared by the FDA will be identified.

Educational Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals and Seattle Genetics.

Research To Practice CME/CNE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

JW Marriott Miami Turnberry
19999 West Country Club Drive
Miami, FL 33180
Hotel Phone: 305-932-6200

Meeting Room
King Ballroom (Conference Level)

Room Reservations
A special discounted room rate of $339 plus applicable taxes and discounted facilities fee of $30 (includes access to the new waterpark) is available to conference attendees at the JW Marriott Miami Turnberry. To secure accommodations, please contact the JW Marriott Miami Turnberry directly at (800) 228-9290 or (305) 932-6200. A personal credit card will be required to secure accommodations.

Please mention you are participating in the General Medical Oncology Conference to receive the special group rate.

Room reservations must be made by Monday, January 20, 2020. A limited number of rooms are available, and we encourage you to make your reservations early. After January 20, 2020, the hotel will offer the best rates based on room availability.

Parking
Overnight discounted valet parking rate of $40.00 per night plus tax, per car is available for conference attendees. Guests are permitted unlimited in-and-out privileges. Daily parking is available to conference attendees at a discounted rate of $20.00 plus tax per car for 1 to 3 hours, $25.00 plus tax per car for 4 to 6 hours or $38 plus tax per car for 7 hours or more. Please note that unfortunately, due to regulatory reporting requirements, Research To Practice is unable to validate parking.





This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Registration Fees

This event is free of charge for practicing physicians, fellows, nurses and other healthcare providers involved in the treatment of cancer.

For all other individuals, including industry professionals,* a conference registration fee of $850 is available through February 1, 2020 and then $950 after that day. All fees processed will be nonrefundable after January 30, 2020 (5:00 PM eastern standard time). To cancel your registration, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.



Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

I am employed by a for-profit organization, including a financial institution, biotech or pharmaceutical company.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.